enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
1.720
-0.020 (-1.15%)
At close: Jun 18, 2026, 4:00 PM EDT
1.725
+0.005 (0.29%)
After-hours: Jun 18, 2026, 7:44 PM EDT
Company Description
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada.
The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC).
Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026.
enGene Therapeutics Inc. is based in Montreal, Canada.
enGene Therapeutics Inc.
| Country | Canada |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Ronald H. Cooper |
Contact Details
Address: 4868 Rue Levy, Suite 220 Montreal, QC H4R 2P1 Canada | |
| Phone | 514 332 4888 |
| Website | engene.com |
Stock Details
| Ticker Symbol | ENGN |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 1980845 |
| CUSIP Number | 29286X101 |
| ISIN Number | CA29286X1015 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ronald H. W. Cooper | President, Chief Executive Officer and Director |
| David Ryan Daws | Chief Financial Officer and Head of Business Development |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Alexander Nichols Ph.D. | Chief Strategy and Operations Officer |
| Joan Connolly | Chief Technology Officer |
| Lee G. Giguere | Chief Legal Officer and Corporate Secretary |
| Tara Place M.B.A. | Senior Vice President of Human Resources |
| Matthew Boyd | Chief Regulatory Officer |
| Jill Buck | Chief Development Officer |
| Amy Pott | Chief Global Commercialization Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2026 | 8-K/A | [Amend] Current report |
| Jun 15, 2026 | 10-Q | Quarterly Report |
| Jun 15, 2026 | 8-K | Current Report |
| Jun 10, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 14, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | SCHEDULE 13G | Filing |
| May 8, 2026 | ARS | Filing |
| May 8, 2026 | DEF 14A | Other definitive proxy statements |
| May 7, 2026 | 8-K | Current Report |